Antiphospholipid antibodies promote tissue factor-dependent angiogenic switch and tumor progression

Yuan Yuan Wu, Andrew V. Nguyen, Xiao Xuan Wu, Mingyu Loh, Michelle Vu, Yiyu Zou, Qiang Liu, Peng Guo, Yanhua Wang, Leslie L. Montgomery, Amos Orlofsky, Jacob H. Rand, Elaine Y. Lin

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Progression to an angiogenic state is a critical event in tumor development, yet few patient characteristics have been identified that can be mechanistically linked to this transition. Antiphospholipid autoantibodies (aPLs) are prevalent in many human cancers and can elicit proangiogenic expression in several cell types, but their role in tumor biology is unknown. Herein, we observed that the elevation of circulating aPLs among breast cancer patients is specifically associated with invasive-stage tumors. By using multiple in vivo models of breast cancer, we demonstrated that aPL-positive IgG from patients with autoimmune disease rapidly accelerates tumor angiogenesis and consequent tumor progression, particularly in slow-growing avascular tumors. The action of aPLs was local to the tumor site and elicited leukocytic infiltration and tumor invasion. Tumor cells treated with aPL-positive IgG expressed multiple proangiogenic genes, including vascular endothelial growth factor, tissue factor (TF), and colony-stimulating factor 1. Knockdown and neutralization studies demonstrated that the effects of aPLs on tumor angiogenesis and growth were dependent on tumor cell-derived TF. Tumor-derived TF was essential for the development of pericyte coverage of tumor microvessels and aPL-induced tumor cell expression of chemokine ligand 2, a mediator of pericyte recruitment. These findings identify antiphospholipid autoantibodies as a potential patient-specific host factor promoting the transition of indolent tumors to an angiogenic malignant state through a TF-mediated pathogenic mechanism.

Original languageEnglish (US)
Pages (from-to)3359-3375
Number of pages17
JournalAmerican Journal of Pathology
Volume184
Issue number12
DOIs
StatePublished - Dec 1 2014

Fingerprint

Antiphospholipid Antibodies
Thromboplastin
Neoplasms
Autoantibodies
Pericytes
Immunoglobulin G
Breast Neoplasms
Macrophage Colony-Stimulating Factor
Microvessels
Chemokines

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

Antiphospholipid antibodies promote tissue factor-dependent angiogenic switch and tumor progression. / Wu, Yuan Yuan; Nguyen, Andrew V.; Wu, Xiao Xuan; Loh, Mingyu; Vu, Michelle; Zou, Yiyu; Liu, Qiang; Guo, Peng; Wang, Yanhua; Montgomery, Leslie L.; Orlofsky, Amos; Rand, Jacob H.; Lin, Elaine Y.

In: American Journal of Pathology, Vol. 184, No. 12, 01.12.2014, p. 3359-3375.

Research output: Contribution to journalArticle

Wu, Yuan Yuan ; Nguyen, Andrew V. ; Wu, Xiao Xuan ; Loh, Mingyu ; Vu, Michelle ; Zou, Yiyu ; Liu, Qiang ; Guo, Peng ; Wang, Yanhua ; Montgomery, Leslie L. ; Orlofsky, Amos ; Rand, Jacob H. ; Lin, Elaine Y. / Antiphospholipid antibodies promote tissue factor-dependent angiogenic switch and tumor progression. In: American Journal of Pathology. 2014 ; Vol. 184, No. 12. pp. 3359-3375.
@article{ac7d6a11f0c84310866d9c8c97e6af8e,
title = "Antiphospholipid antibodies promote tissue factor-dependent angiogenic switch and tumor progression",
abstract = "Progression to an angiogenic state is a critical event in tumor development, yet few patient characteristics have been identified that can be mechanistically linked to this transition. Antiphospholipid autoantibodies (aPLs) are prevalent in many human cancers and can elicit proangiogenic expression in several cell types, but their role in tumor biology is unknown. Herein, we observed that the elevation of circulating aPLs among breast cancer patients is specifically associated with invasive-stage tumors. By using multiple in vivo models of breast cancer, we demonstrated that aPL-positive IgG from patients with autoimmune disease rapidly accelerates tumor angiogenesis and consequent tumor progression, particularly in slow-growing avascular tumors. The action of aPLs was local to the tumor site and elicited leukocytic infiltration and tumor invasion. Tumor cells treated with aPL-positive IgG expressed multiple proangiogenic genes, including vascular endothelial growth factor, tissue factor (TF), and colony-stimulating factor 1. Knockdown and neutralization studies demonstrated that the effects of aPLs on tumor angiogenesis and growth were dependent on tumor cell-derived TF. Tumor-derived TF was essential for the development of pericyte coverage of tumor microvessels and aPL-induced tumor cell expression of chemokine ligand 2, a mediator of pericyte recruitment. These findings identify antiphospholipid autoantibodies as a potential patient-specific host factor promoting the transition of indolent tumors to an angiogenic malignant state through a TF-mediated pathogenic mechanism.",
author = "Wu, {Yuan Yuan} and Nguyen, {Andrew V.} and Wu, {Xiao Xuan} and Mingyu Loh and Michelle Vu and Yiyu Zou and Qiang Liu and Peng Guo and Yanhua Wang and Montgomery, {Leslie L.} and Amos Orlofsky and Rand, {Jacob H.} and Lin, {Elaine Y.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.ajpath.2014.07.027",
language = "English (US)",
volume = "184",
pages = "3359--3375",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Antiphospholipid antibodies promote tissue factor-dependent angiogenic switch and tumor progression

AU - Wu, Yuan Yuan

AU - Nguyen, Andrew V.

AU - Wu, Xiao Xuan

AU - Loh, Mingyu

AU - Vu, Michelle

AU - Zou, Yiyu

AU - Liu, Qiang

AU - Guo, Peng

AU - Wang, Yanhua

AU - Montgomery, Leslie L.

AU - Orlofsky, Amos

AU - Rand, Jacob H.

AU - Lin, Elaine Y.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Progression to an angiogenic state is a critical event in tumor development, yet few patient characteristics have been identified that can be mechanistically linked to this transition. Antiphospholipid autoantibodies (aPLs) are prevalent in many human cancers and can elicit proangiogenic expression in several cell types, but their role in tumor biology is unknown. Herein, we observed that the elevation of circulating aPLs among breast cancer patients is specifically associated with invasive-stage tumors. By using multiple in vivo models of breast cancer, we demonstrated that aPL-positive IgG from patients with autoimmune disease rapidly accelerates tumor angiogenesis and consequent tumor progression, particularly in slow-growing avascular tumors. The action of aPLs was local to the tumor site and elicited leukocytic infiltration and tumor invasion. Tumor cells treated with aPL-positive IgG expressed multiple proangiogenic genes, including vascular endothelial growth factor, tissue factor (TF), and colony-stimulating factor 1. Knockdown and neutralization studies demonstrated that the effects of aPLs on tumor angiogenesis and growth were dependent on tumor cell-derived TF. Tumor-derived TF was essential for the development of pericyte coverage of tumor microvessels and aPL-induced tumor cell expression of chemokine ligand 2, a mediator of pericyte recruitment. These findings identify antiphospholipid autoantibodies as a potential patient-specific host factor promoting the transition of indolent tumors to an angiogenic malignant state through a TF-mediated pathogenic mechanism.

AB - Progression to an angiogenic state is a critical event in tumor development, yet few patient characteristics have been identified that can be mechanistically linked to this transition. Antiphospholipid autoantibodies (aPLs) are prevalent in many human cancers and can elicit proangiogenic expression in several cell types, but their role in tumor biology is unknown. Herein, we observed that the elevation of circulating aPLs among breast cancer patients is specifically associated with invasive-stage tumors. By using multiple in vivo models of breast cancer, we demonstrated that aPL-positive IgG from patients with autoimmune disease rapidly accelerates tumor angiogenesis and consequent tumor progression, particularly in slow-growing avascular tumors. The action of aPLs was local to the tumor site and elicited leukocytic infiltration and tumor invasion. Tumor cells treated with aPL-positive IgG expressed multiple proangiogenic genes, including vascular endothelial growth factor, tissue factor (TF), and colony-stimulating factor 1. Knockdown and neutralization studies demonstrated that the effects of aPLs on tumor angiogenesis and growth were dependent on tumor cell-derived TF. Tumor-derived TF was essential for the development of pericyte coverage of tumor microvessels and aPL-induced tumor cell expression of chemokine ligand 2, a mediator of pericyte recruitment. These findings identify antiphospholipid autoantibodies as a potential patient-specific host factor promoting the transition of indolent tumors to an angiogenic malignant state through a TF-mediated pathogenic mechanism.

UR - http://www.scopus.com/inward/record.url?scp=84913582180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84913582180&partnerID=8YFLogxK

U2 - 10.1016/j.ajpath.2014.07.027

DO - 10.1016/j.ajpath.2014.07.027

M3 - Article

VL - 184

SP - 3359

EP - 3375

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 12

ER -